TR EN AR RU KK

CRWDCrowdStrike Holdings, Inc.

🇺🇸 US
Smart Money 44
225.76
USD
Analysis Scores
Lothien Robustness Score?
-
Neden bu skor?
Damodaran ?
-
Dalio Risk ?
-
Piotroski ?
4/9
Neutral
Previous period ROA data missing (C1 delta-ROA); Previous year data missing → margin comparison unavailable (C8)
Graham ?
$2.5
Pahalı
Lothien Robustness Summary
46/100
Lothien Sağlamlık: Orta (46/100)
Karışık sinyaller. Hem olumlu hem olumsuz göstergeler mevcut. | Kısa Vade: Olumlu | Uzun Vade: Olumlu | Pozitif: 4 | Negatif: 7 | Nötr: 2
Net Kâr Pozitif
Son çeyrekte $5M net kâr açıklandı. Şirket kârlı.
Çeyreklik Kâr Düşüşü
Net kâr bir önceki çeyreğe göre %-80.9 geriledi ($28M → $5M). Kısa vadede olumsuz sinyal.
Yıllık Kâr Büyümesi Güçlü
Geçen yılın aynı dönemine göre net kâr %+107.6 arttı. Büyüme trendi sağlıklı.
Çok Düşük Net Kâr Marjı
Net kâr marjı sadece %0.4. Küçük bir maliyet artışı şirketi zarara sokabilir.
Net Nakit Pozisyonu
Şirketin nakdi borçlarından $4.2B fazla. Borç riski düşük.
Güçlü Nakit Üretimi
Serbest nakit akışı ($376M) kârın %7093'sini nakit olarak üretiyor. Kâr kalitesi yüksek.
Yüksek F/K Uyarısı
Trailing F/K: 100.0. Piyasa yüksek büyüme bekliyor ya da hisse pahalı. Büyüme gerçekleşmezse düşüş riski yüksek.
Yüksek PD/DD
PD/DD: 45.88. Piyasa defter değerinin çok üstünde fiyatlıyor. Büyüme beklentisi primli.
Yüksek EV/EBITDA
EV/EBITDA: 526.2. Pahalı değerleme.
Düşük ROE
ROE: %0.7. Sermaye getirisi yetersiz — enflasyonun altında.
Lothien Sağlamlık Skoru: 28/100
Bileşik algoritma değerlendirmesine göre şirketin finansal yapısı zayıf görünüyor.
Mevsimsel Etki
Çeyreklik düşüş (%-80.9) ama yıllık bazda artış (%+107.6). Bu muhtemelen mevsimsel bir düşüş.
Sonraki Çeyrek: Düşüş Beklentisi
Tahminine göre kâr %-373.3 düşebilir. Sonraki bilançoya dikkat.

Data date date not measured Not investment advice; the figures are rule-based model output. How the scores are computed

Score record
Method How the scores are computed · Scorecard
Data date date not measured
Update frequency Scheduled analysis run on business days at 19:30 Istanbul time; not every symbol is refreshed in every run

Method summaryThe Lothien Robustness Score (0-100) is a weighted combination of sub-scores computed by fixed rules from published financial statements and price data (Damodaran valuation, Dalio risk, Piotroski F-score, earnings quality, momentum and others). The rules are applied automatically to every covered stock, with weights that vary by sector.

AssumptionsCalculations rest on the company's latest published financial statements and on price data that may be delayed. Where four quarters have not been published, annual figures may be scaled from the available quarters. Model parameters such as the risk-free rate, the risk premium and long-term growth are fixed assumptions per exchange and contain no company-specific expectation.

Conflict of interestNo statement has been published on whether MIDAK, the operator of Lothien, or its team hold positions in these stocks. The figures are produced automatically by the same rules, without regard to any such position.

WarningThis information is not within the scope of investment advisory services and is not investment advice. The figures are the output of rule-based models and may not suit your financial situation or your risk and return preferences. Making an investment decision on the basis of this information alone may not lead to results that meet your expectations.

Model output; not investment advice; different models can disagree. Report an error

Risk Analysis (VaR) Çok Yüksek
252 days
Annual Volatility ?
%57.5
VaR 95% ?
%5.68
daily max loss
VaR 99% ?
%8.15
daily max loss
CVaR 95% ?
%7.14
expected loss (tail)
Max Drawdown ?
%37.2
10.11.2025 → 24.02.2026
Skewness ?
0.80
Parametrik%5.68
Historik%5.27
Cornish-Fisher%4.50
Return Distribution
Valuation
Potential?
-
Balance Sheet Analysis? Q2026/9
Son 3 çeyrek ardışık kâr
Fiyat TRAMA-99 altında: %-7.3 — teknik trend olumsuz
Direnç seviyesi: TRAMA-99 = 243.65 USD
Fundamental & Technical Analysis
Profitability
Net Profit Margin %0.4
Net profit margin %0.4 — positive but low. Compared to previous quarter -1.6 point decrease.
ROE - Return on Equity (TTM) %0.7
ROE %0.7 — low return on equity.
EBITDA Margin %7.2
EBITDA margin %7.2 — moderate operational efficiency.
Gross Profit Margin %74.6
Gross profit per revenue %74.6. Strong pricing power.
Free Cash Flow Margin (TTM) %28.2
TTM Free Cash Flow is %28.2'i. Strong FCF generation — profit quality is high.
Valuation
P/E Ratio 100.0x Sector: 26.3x
F/K 100.0x — sector median's (26.3x) %280 above. Expensive zone.
P/B Ratio 45.88x Sector: 4.55x
PD/DD 45.88x — sector median's %908 above. Expensive book value.
Indebtedness
Current Ratio 1.57x
Current ratio 1.57x — can comfortably cover short-term debts.
Net Debt / EBITDA 1.9x
Net Debt/EBITDA 1.9x — manageable debt level.
Debt / Equity 0.16x
Low leverage — majority of assets financed by equity.
Interest Coverage 19.4x
Interest coverage 19.4x — very wide margin for paying interest expenses.
Growth
Revenue Growth (YoY) %+25.8
Revenue YoY %25.8 grew — healthy growth rate.
Net Profit Growth (YoY) %+107.6
Net profit turned from loss to profit (2026/7). Significant improvement.
Score Explanations
Lothien Robustness
-
Weak robustness (28/100). Valuation metrics and/or debt profile are unfavorable; caution is needed.
Potential
-
Minus %51.8 expected value (110.29) vs current price comparison. 3/4 valuation models could be calculated. Model confidence %69.
Components: PE target: 57.15 | P/B target: 57.15 | EV/EBITDA target: 57.15
Damodaran Valuation
-
Low Damodaran score (8/100). ROIC (%-7.9) below cost of capital. DCF analysis does not support current price.
Very Weak
Dalio Risk Analysis
-
Low debt risk (80/100). Interest coverage ratio 19.4x — strong. Debt/EBITDA 1.9x — in healthy range.
Leverage: 86/100 | Debt Service: 89/100 | Quality: 29/100
ROIC - Return on Capital
%-7.9
ROIC (%-7.9) cost of capital (9.8%) below → destroying value.
WACC: %9.8
Debt Cycle Phase
Early Expansion
Debt decreasing, growth gaining momentum. Company in balance sheet cleanup phase.
Piotroski F-Score
4/9
Weak Piotroski (4/9). Many balance sheet quality criteria not met. Note: Previous period ROA data missing (C1 delta-ROA); Previous year data missing → margin comparison unavailable (C8)
Neutral
Graham Intrinsic Value
$2.5
Expensive
⚖️ Sector Comparison
P/E Ratio
100.0x vs 26.3x
Sector median's %280 above — expensive
P/B Ratio
45.88x vs 4.55x
Compared to sector %908 more expensive (by book value)
EV/EBITDA
526.2x vs 15.6x
Compared to sector %3266 higher EV/EBITDA
ROIC vs WACC
%-7.9 vs %9.8 WACC
ROIC 17.7 bps below cost of capital
Net Profit Margin (TTM)
%1.1 vs %8.1 EBITDA margin
TTM net profit margin %1.1
TRAMA-99 Trend — Downtrend
Price (225.76), TRAMA-99 line's %7.3 below. Downtrend ongoing — technical outlook negative. Pressure may continue until TRAMA is broken above.
Price:: 225.76
TRAMA: 243.65
Difference: %-7.3
Charts
Indicators
BB deviation ?
RSI thresholds ?

Price Chart ?
▲ içeriden alım · ▼ içeriden satım · ★ katalizör (haber-sezgisel) · ■ 13D aktivist · ■ 13G pasif — SEC Form 4 ~2 gün gecikmeli, yalnız yönetici/direktör/%10+ sahip; katalizör = haber-sezgisel; 13D/G = %5+ pay bildirimi ~5 iş günü gecikmeli.
RSI (14) ?
Bollinger Bands ?
MACD ?
Gold-Based Price + TRAMA (Stock / Gram Gold) ?
Kurumsal Holdings — 13F (çeyreklik) ?

İçeriden Alım-Satım Akışı

Kim aldı, kim sattı, ne kadar

CRWD — Participation Finance Compliance
Loading…
The Lothien health scores and analyses on this page are for informational purposes only. They do not constitute investment advice. Please consult a licensed investment advisor before making investment decisions.